H–1Bs for Physicians and the Healthcare Workforce Act

1) What happened: On March 17, 2026, Rep. Lawler (R-NY) introduced HR7961, the H-1Bs for Physicians and the Healthcare Workforce Act. The bill was referred to the House Judiciary Committee. It has 38 cosponsors, including both Republicans and Democrats, suggesting moderate bipartisan support. The bill is in early stage with no further action since referral. 2) The money trail: This bill does not authorize or appropriate any federal funding. Instead, it removes a regulatory cost — the $100,000 fee imposed by a September 2025 Presidential Proclamation on H-1B visa holders. By exempting healthcare workers from this fee, the bill reduces hiring costs for healthcare employers. The savings flow directly to companies' bottom lines. No taxpayer funds are involved. 3) Structural winners: Hospital operators like HCA ($HCA) and health insurers with provider networks like UnitedHealth Group are primary beneficiaries as they directly employ foreign physicians and nurses. Medical device and pharmaceutical companies like Johnson & Johnson and Abbott Laboratories ($ABT) benefit from access to foreign researchers and clinical staff. The bill does not create new spending but reduces regulatory burden. 4) Competitive landscape: The bill levels the playing field for US healthcare employers competing for global talent. Companies with large hospital networks (HCA, UNH's Optum) gain the most as they face chronic staffing shortages. Smaller rural hospitals may benefit disproportionately but are not publicly traded. The bill does not affect drug pricing or insurance reimbursement. 5) Timeline: The bill is in early stage — referred to committee with no hearings scheduled. Passage probability is moderate given bipartisan cosponsorship but uncertain in a divided Congress. Next steps: committee markup, House floor vote, Senate companion bill (none yet), and presidential action. Timeline: unlikely to pass before 2027.